ES2721922T3 - Tratamiento o prevención del daño neuronal no inflamatorio por traumatismo cerebral e ictus utilizando mentol, linalool y/o icilina - Google Patents

Tratamiento o prevención del daño neuronal no inflamatorio por traumatismo cerebral e ictus utilizando mentol, linalool y/o icilina Download PDF

Info

Publication number
ES2721922T3
ES2721922T3 ES14726347T ES14726347T ES2721922T3 ES 2721922 T3 ES2721922 T3 ES 2721922T3 ES 14726347 T ES14726347 T ES 14726347T ES 14726347 T ES14726347 T ES 14726347T ES 2721922 T3 ES2721922 T3 ES 2721922T3
Authority
ES
Spain
Prior art keywords
linalool
stroke
treatment
icilin
menthol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14726347T
Other languages
English (en)
Inventor
Susana Camacho
Gonzalez Stéphanie Michlig
Coutre Johannes Le
Henry Markram
Maurizio Pezzoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Application granted granted Critical
Publication of ES2721922T3 publication Critical patent/ES2721922T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Vascular Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición para su uso en el tratamiento del daño neuronal no inflamatorio por una afección seleccionada del grupo que consiste en traumatismo cerebral, un ictus y una combinación de los mismos, comprendiendo la composición una cantidad terapéuticamente eficaz de linalool.
ES14726347T 2013-05-24 2014-05-23 Tratamiento o prevención del daño neuronal no inflamatorio por traumatismo cerebral e ictus utilizando mentol, linalool y/o icilina Active ES2721922T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361827232P 2013-05-24 2013-05-24
PCT/EP2014/060637 WO2014187945A1 (en) 2013-05-24 2014-05-23 Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using menthol, linalool and/or icilin

Publications (1)

Publication Number Publication Date
ES2721922T3 true ES2721922T3 (es) 2019-08-06

Family

ID=50819728

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14726347T Active ES2721922T3 (es) 2013-05-24 2014-05-23 Tratamiento o prevención del daño neuronal no inflamatorio por traumatismo cerebral e ictus utilizando mentol, linalool y/o icilina

Country Status (10)

Country Link
US (2) US20160166570A1 (es)
EP (1) EP3003292B1 (es)
JP (2) JP2016520588A (es)
CN (1) CN105228601A (es)
AU (2) AU2014270341A1 (es)
BR (1) BR112015026484A2 (es)
CA (1) CA2908365C (es)
ES (1) ES2721922T3 (es)
TR (1) TR201906539T4 (es)
WO (1) WO2014187945A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201906539T4 (tr) * 2013-05-24 2019-05-21 Nestec Sa Mentol, Linalool ve/veya Icilin Kullanarak Beyin Travması ve İnmelerden Kaynaklanan Non-İnflamatuar Nöron Hasarının Tedavisi veya Önlenmesi.
US20230133657A1 (en) * 2020-03-24 2023-05-04 China Medical University The use of menthol for the preparation of a topical composition to improve neurodegenerative disease and stroke

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090599A2 (en) * 2002-04-25 2003-11-06 Brainsgate Ltd. Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
JP4742204B2 (ja) * 2005-01-21 2011-08-10 財団法人ヒューマンサイエンス振興財団 脂肪細胞分化制御剤
JP2007291069A (ja) * 2006-03-31 2007-11-08 Daiichi Sankyo Healthcare Co Ltd 抗酸化剤および／または消炎鎮痛剤組成物
GB0615136D0 (en) * 2006-07-29 2006-09-06 Univ Edinburgh Induction of analgesia in neuropathic pain
KR20090085237A (ko) * 2008-02-04 2009-08-07 김병문 천연 진주가루를 함유한 뇌질환 예방 및 치료용 한약조성물
WO2011006073A1 (en) * 2009-07-10 2011-01-13 President And Fellows Of Harvard College Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
KR20120103317A (ko) * 2011-03-10 2012-09-19 한국생명공학연구원 아실 코에이:콜레스테롤 아실트랜스퍼라제 저해활성을 갖는 고수씨 추출물 또는 이로부터 분리된 리나로올을 포함하는 조성물
ME03038B (me) * 2011-12-19 2018-10-20 Dompe Farm Spa Antagonisti trpm8
CN102512634A (zh) * 2011-12-26 2012-06-27 神威药业（张家口）有限公司 复方麝香软胶囊及其制备方法
US20150320700A1 (en) * 2012-05-07 2015-11-12 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Reserc Organizatio Geranium oil and constituents thereof for treatment of neurodegenerative diseases
TR201906539T4 (tr) * 2013-05-24 2019-05-21 Nestec Sa Mentol, Linalool ve/veya Icilin Kullanarak Beyin Travması ve İnmelerden Kaynaklanan Non-İnflamatuar Nöron Hasarının Tedavisi veya Önlenmesi.

Also Published As

Publication number Publication date
CA2908365A1 (en) 2014-11-27
EP3003292B1 (en) 2019-03-20
EP3003292A1 (en) 2016-04-13
US20170189403A1 (en) 2017-07-06
AU2019222781A1 (en) 2019-09-12
JP2020011985A (ja) 2020-01-23
US20160166570A1 (en) 2016-06-16
BR112015026484A2 (pt) 2017-07-25
WO2014187945A1 (en) 2014-11-27
US10799502B2 (en) 2020-10-13
AU2019222781B2 (en) 2021-05-13
AU2014270341A1 (en) 2015-10-08
CA2908365C (en) 2023-02-28
JP2016520588A (ja) 2016-07-14
CN105228601A (zh) 2016-01-06
TR201906539T4 (tr) 2019-05-21

Similar Documents

Publication Publication Date Title
CL2019001079A1 (es) Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina.
CL2020000215A1 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
UY35916A (es) Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
NI201600071A (es) Compuestos de inhibidor de autotaxina
DOP2016000253A (es) Nuevos compuestos
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
NI201500140A (es) Compuestos y composiciones terapéuticos
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CL2016001151A1 (es) Derivados de purina 2,6-sustituidos y su uso en el tratamiento de trastorno proliferativos.
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
CR20150496A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
PE20150721A1 (es) Composicion farmaceutica que comprende gemigliptina y metformina, y metodo para su preparacion